Shares in Oxford Biomedica (OXB) saw a double-digit rise after Danish life sciences investment group Novo Holdings A/S bought a 10 per cent stake in the gene/cell therapy group for £53.5m. The proceeds will be used to repay the existing debt facility with Oaktree Capital Management and to further develop the LentiVector platform and the proprietary product portfolio. Novo Holdings has agreed to subscribe for 6.57m new ordinary shares in OXB.
IC TIP:
Hold
at
760p